HIV - Prevention

In what ways do you actively prevent HIV transmission?

Share your story with others:

MedicineNet appreciates your comment. Your comment may be displayed on the site and will always be published anonymously.Patient Comments FAQs

Enter your Comment

Tell us a bit about your background to make your comments more useful to other MedicineNet users. (Optional)

Screen Name: *

Gender of Patient: Male Female

Age Range of Patient:

I am a: Patient Caregiver


* Screen Name will appear next to the published comment. Please do not include your full name or email address.

By submitting your comment, and other materials (collectively referred to as a "Submission") to MedicineNet, you grant MedicineNet permission to use, copy, transmit, publish, display, edit and modify your Submission in connection with its Web site. MedicineNet will not pay you for your Submission. You represent that you have all rights necessary for MedicineNet to use your Submission as set forth above.

Please keep these guidelines in mind when writing your comment:

  • Please make sure you address the question asked.
  • Due to the overwhelming number of comments received, not all comments will be published.
  • When selecting comments to publish, our staff will choose those that are educational and complement the topic. Please try to stay on topic.
  • Your comment may be edited. We would typically edit comments to make them clearer and more readable. We will remove personal information such as last names, email and web addresses, and other potentially harmful information.
  • We will not notify you if your comment has been published. We suggest that you check back on the topic article regularly.
  • We do not provide medical or healthcare advice, treatment, or diagnosis.

Thank you for participating!


I have read and agree to abide by the MedicineNet Terms and Conditions and the MedicineNet Privacy Policy (required).

To prevent our systems from spam, please complete the following prior to submitting your comment.

Please select the white triangle:

What is in the future for preventing HIV transmission?

Early advances in preventing HIV transmission resulted from educational programs describing how transmission occurs and providing barrier protection for those exposed to genital secretions and new needles or bleach to those exposed to blood by sharing needles. Despite these efforts, new infection in both the developed and developing worlds has continued at high rates.

Historically, the greatest success in preventing viral transmission has resulted from the development of preventative vaccines. Unfortunately, decades of research to develop an HIV vaccine has led to little hope for success. In 2007, a major setback in this area occurred when the STEP study investigating a promising vaccine candidate was prematurely stopped due to the lack of evidence that it produced any protection from HIV infection. In contrast, a glimmer of hope did emerge with the report in 2009 of the results of the RV 144 Thai HIV vaccine trial which demonstrated borderline effectiveness in the more than 16,000 recipients. While this vaccine demonstrated only limited evidence of protection, research is under way to further explore what can be learned for future vaccine development from this modest success.

In light of the limited ability of counseling and testing to curb the spread of the HIV pandemic, many researchers have moved toward other biologic strategies for preventing HIV that do not rely solely on people changing their behavior. It is in this area where there has been some success. During the last 10 years, there were several large studies showing that male circumcision along with behavioral counseling reduced the risk of heterosexual men acquiring HIV infection. This provides a novel prevention strategy for at-risk, HIV-uninfected heterosexual men. Since the summer of 2010, there have been several other promising advances in the field of HIV prevention. This included the CAPRISA 004 study which showed that vaginal administration before and after intercourse of a gel containing the antiretroviral agent tenofovir reduced the risk of transmission of both HIV and herpes simplex virus to heterosexual women. Other studies are under way to confirm the results of this study as well as to determine whether the results are any different if the agent is administered daily rather than simply around the time of intercourse. One such study was recently stopped by a Data Safety and Monitoring Board because it was shown that the study would not be able to show that once-daily tenofovir vaginal gel demonstrated protection from infection compared to placebo gel. The reasons for this finding are not yet known and could be from poor adherence with the therapy, differences in protection based upon the dosing schedule or a combination of these and other factors.

In the fall of 2010, the iPrEx study reported the results of the first large study testing the effectiveness of pre-exposure prophylaxis, so called "PrEP." In this study, HIV-uninfected men who had sex with men who took TDF/FTC once daily along with a comprehensive program to promote safe sex practices and early treatment of sexually transmitted diseases experienced a markedly reduced risk of acquiring HIV compared with those receiving similar prevention practice without TDF/FTC. There are several other studies under way testing the safety and effectiveness of PrEP in other at-risk groups such as heterosexuals and intravenous drug users. One such study was recently presented that assessed the protective effect of TDF or TDF/FTC compared to placebo, each given once daily to HIV-uninfected men and women in stable relationships with infected individual. This study demonstrated significant levels of protection for both drugs in this population. In contrast, another study in high-risk HIV-uninfected women was stopped prematurely by an independent Data Safety and Monitoring Committee because of no apparent protection provided to this population from TDF/FTC compared with placebo. The differences in the outcomes of this study are not completely clear, but recently presented data suggest that much of it may be related to very low levels of adherence to medications by the study participants. These data are very new, results are conflicting, and there are always potential concerns of long-term toxicity associated with HIV-uninfected individuals taking these medications. For now the use of antiretrovirals for PrEP is not yet approved or considered the standard of care. A great deal of discussion will ensue over the coming months between government agencies, academia, industry, and the community to determine how PrEP should move forward.

Another potential way to consider the use of antiretroviral agents to prevent HIV transmission is by using them in infected individuals to reduce the levels of virus in blood and vaginal secretions and thus the transmissibility to others. Until recently there were imperfect studies that strongly suggested that people on effective treatment are less likely to transmit to others. More recently, the results of a large study were published demonstrating unequivocally that those started on treatment are less likely to transmit to their stable HIV-uninfected partners than those who were not on treatment. In fact, it appeared to be approximately 96% protective. This type of data has increased interest in advancing studies to enhance testing for HIV, early engagement into care and initiation of therapy to reduce transmission in the community, so called "test-and-treat" strategy. The feasibility of this approach and the potential impact on the epidemic of new infections is currently being explored. It is worth noting that although effective antiretroviral therapy almost certainly reduces the risk of HIV transmission, such individuals should still use standard precautions (for example, condoms to avoid transmission to partners).

A final prevention strategy of last resort is the use of antiretrovirals as post-exposure prophylaxis, so-called "PEP," to prevent infection after a potential exposure to HIV-containing blood or genital secretions. Animal studies and some human experience suggest that PEP may be effective in preventing HIV transmission, and it is based upon these limited data that current recommendations have been developed for health care workers and people in the community exposed to potentially infectious material. Current guidelines suggest that those experiencing a needle stick or who are sexually exposed to genital secretions of an HIV-infected person should take antiretrovirals for four weeks. Those individuals considering this type of preventative treatment, however, must be aware that post-exposure treatment cannot be relied upon to prevent HIV infection. Moreover, such treatment is not always available at the time it is most needed and is probably best restricted to unusual and unexpected exposures, such as a broken condom during intercourse. If PEP is to be initiated, it should occur within hours of exposure and certainly within the first several days. Updated guidelines are published and available at http://www.aidsinfo.nih.gov.

Previous contributing medical editor: Leslie J. Schoenfield, MD, PhD

Return to Human Immunodeficiency Virus

Stay Informed!

Get the latest health and medical information delivered direct to your inbox FREE!